About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 122 record(s)
Req # A-2021-002089
Adverse Drug Reactions (ADRs). Report numbers: E2B_04589505, E2B_04502484, E2B_04531727, E2B_04514759, E2B_04526131, E2B_04554068, E2B_04587649, E2B_04507344, E2B_04535845, E2B_04582010, E2B_04586624, E2B_04589724, E2B_04595289, E2B_04510385, E2B_04505282, E2B_04530645, E2B_04604190, E2B_04595174, E2B_04551664, E2B_04501753.Organization: Health Canada
June 2022
Req # A-2021-002113
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-101405-155.Organization: Health Canada
June 2022
Req # A-2021-002120
Adverse Drug Reactions (ADRs) for MEZAVANT. Report numbers: E2B_04896613, 000976403, E2B_04897681, E2B_04949352. ADRs for MESALAZINE. Report numbers: E2B_04913358, E2B_04893915, E2B_04949285, E2B_04948923, E2B_04949165, E2B_04853429, E2B_04927079, E2B_04945433, 000974732, 000974426, 000975311, 000975622, 000975677, 000975892, 000975684.Organization: Health Canada
June 2022
Req # A-2021-002123
Adverse Drug Reactions (ADRs). Report numbers: 000937683, 000941334, 000952520, 000963602.Organization: Health Canada
June 2022
Req # A-2021-002142
Adverse Drug Reactions (ADRs) for ZOPICLONE, BUDESONIDE, QUADRIVALENT INFLUENZA VACCINE. Report numbers: E2B_04821402, E2B_04819777, E2B_04546577, 000974506.Organization: Health Canada
June 2022
Req # A-2021-002153
Adverse Drug Reactions (ADRs) for ALEMTUZUMAB, ALIROCUMAB, CABAZITAXEL, ENOXAPARIN SODIUM, FUROSEMIDE. Report numbers: 000967750, E2B_04898115, 000975008, E2B_04904547, E2B_04685448, 000976602, 000975238, E2B_04647826, E2B_04632578.Organization: Health Canada
June 2022
Req # A-2022-000001
Adverse Drug Reactions (ADRs) for METFORMIN, METFORMIN HYDROCHLORIDE, METOLAZONE, RANITIDINE. Report numbers: E2B_04799227, E2B_04906981, E2B_04913738, E2B_04888052, E2B_04781178, 000975040, E2B_04811723, E2B_04799802, E2B_04921453, E2B_04925972.Organization: Health Canada
June 2022
Req # A-2022-000004
Adverse Drug Reactions (ADRs) for METFORMIN, METFORMIN HYDROCHLORIDE, METOLAZONE, RANITIDINE. Report numbers: 000977292, E2B_03623086, E2B_04657718, E2B_04724520, 000973481, E2B_04683448, E2B_04683292.Organization: Health Canada
June 2022
Req # A-2022-000005
Adverse Drug Reactions (ADRs) for RANITIDINE HYDROCHLORIDE, ZOPICLONE. Report numbers: E2B_04938746, E2B_04772196, E2B_04821402, E2B_04675804, E2B_04793351.Organization: Health Canada
June 2022
Req # A-2022-000010
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-102424-617, Digital Transformation Branch Structure.Organization: Health Canada
June 2022